APA (7th ed.) Citation

L, D. C., J, E. P., MT, T. F., X, C. G., JP, M., V, P. S., . . . A, S. M. (2025). Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: The RML-TB trial protocol. BMJ open respiratory research, 12(1), . https://doi.org/10.1136/bmjresp-2024-002475

Chicago Style (17th ed.) Citation

L, Diab Casares, et al. "Multicentre Controlled Open Randomised Clinical Trial to Assess Efficacy and Safety of an Anti-tuberculosis Drug Combination Based on Optimised-dose Rifampicin, Optimised-dose Moxifloxacin and Optimised-dose Linezolid for TB: The RML-TB Trial Protocol." BMJ Open Respiratory Research 12, no. 1 (2025). https://doi.org/10.1136/bmjresp-2024-002475.

MLA (9th ed.) Citation

L, Diab Casares, et al. "Multicentre Controlled Open Randomised Clinical Trial to Assess Efficacy and Safety of an Anti-tuberculosis Drug Combination Based on Optimised-dose Rifampicin, Optimised-dose Moxifloxacin and Optimised-dose Linezolid for TB: The RML-TB Trial Protocol." BMJ Open Respiratory Research, vol. 12, no. 1, 2025, https://doi.org/10.1136/bmjresp-2024-002475.